Letrozole-Oncology

• Breast Cancer (Hormone Receptor-Positive)
• Adjuvant Breast Cancer Treatment
• Aromatase Inhibitor Therapy
• Postmenopausal Breast Cancer

Letrozole (brand name Femara) is a third-generation, nonsteroidal aromatase inhibitor used as adjuvant, extended adjuvant, and palliative endocrine therapy for hormone receptor-positive breast cancer in postmenopausal women. Daily oral dosing reduces circulating estrogen by more than 95 percent, depriving estrogen-dependent tumor cells of the growth signal they require. Among the three available aromatase inhibitors - letrozole, anastrozole, and exemestane - letrozole is the most potent on serum estradiol suppression and remains a cornerstone of long-term hormonal management for early-stage and advanced disease. It is taken once daily, requires no titration, and has a generally predictable side-effect profile dominated by hot flashes, joint stiffness, and accelerated bone loss.

Mechanism of Action

In premenopausal women, the ovaries produce estradiol directly under the influence of pituitary gonadotropins. After menopause, ovarian production drops sharply and the body's remaining estrogen comes from peripheral conversion of adrenal androstenedione and testosterone into estrone and estradiol by the aromatase enzyme - a cytochrome P450 family enzyme expressed in adipose tissue, muscle, liver, breast, and brain. Letrozole reversibly binds the heme group of aromatase, blocking this conversion and reducing circulating estrogens to nearly undetectable concentrations within a few weeks of daily dosing.

For estrogen receptor-positive breast cancers, this profound estrogen deprivation slows or stops tumor proliferation and, over time, induces apoptosis of hormone-dependent cells. Letrozole does not affect adrenal corticosteroid or aldosterone synthesis, distinguishing it from earlier nonselective inhibitors. Because nearly all systemic estrogen is suppressed, downstream effects on estrogen-responsive tissues - bone, vaginal mucosa, lipids, and the cardiovascular endothelium - account for most of the drug's adverse effect profile. Detailed clinical pharmacology is available in the FDA prescribing information at accessdata.fda.gov and the American Cancer Society provides patient-facing summaries of how aromatase inhibitors fit into modern breast cancer care. The drug is metabolized by CYP2A6 and CYP3A4, but no clinically significant interactions have been demonstrated at therapeutic doses with most commonly co-prescribed medications. Notably, letrozole has no estrogenic activity itself, distinguishing it from selective estrogen receptor modulators such as tamoxifen, which can act as agonists in endometrial tissue.

Clinical Use

For postmenopausal women with hormone receptor-positive early breast cancer, letrozole is one of three preferred initial adjuvant endocrine options, alongside anastrozole and the steroidal aromatase inhibitor exemestane. Standard duration is five years for low-risk disease and may extend to seven to ten years for higher-risk node-positive cases. Compared with tamoxifen, aromatase inhibitors produce slightly better disease-free survival and lower recurrence rates in postmenopausal women but increase joint pain, bone loss, and vaginal dryness. Sequential therapy - tamoxifen for two to three years followed by letrozole, or letrozole first followed by tamoxifen - is an alternative for patients with troublesome musculoskeletal side effects.

In metastatic disease, letrozole is a standard first- or second-line endocrine partner for CDK4/6 inhibitors such as palbociclib, ribociclib, or abemaciclib, with combination regimens producing progression-free survival in excess of two years for many patients. Patient selection favors postmenopausal status confirmed biochemically when uncertain, ER-positive or PR-positive tumor biology, and tolerable bone health at baseline. Letrozole is contraindicated in premenopausal women and in pregnancy, and aromatase inhibitors offer no benefit in ER-negative disease. The National Cancer Institute summarizes guideline-based decision making at cancer.gov. Patients with severe pre-existing osteoporosis, brittle bone fractures, or extreme arthralgia history may be better served starting with tamoxifen. Letrozole is also widely used off-label for ovulation induction in women with infertility, particularly in polycystic ovary syndrome, where it has supplanted clomiphene as preferred therapy in many practices; however, this use is by reproductive specialists and falls outside the oncology indication discussed here.

How to Take It

Letrozole is given as a 2.5 mg tablet once daily at the same time of day, with or without food. The tablet should be swallowed whole with water. If a dose is missed and it is within several hours of the usual time, take it; if it is closer to the next dose, skip and resume the regular schedule - never double up. Continuous daily dosing without breaks is essential because circulating estrogen rebounds rapidly when the drug is discontinued. Treatment duration is determined by stage and risk, ranging from five years adjuvantly to indefinite use in metastatic disease until progression.

Most patients tolerate the first week well, but new or worsening hot flashes, joint stiffness particularly in the hands on first waking, and mild fatigue often emerge over the first one to three months. Many patients find symptoms plateau or partially improve by six months. Strategies that help include daily exercise - especially low-impact resistance training - regular sleep, hydration, and avoiding alcohol and trigger foods for hot flashes. Vaginal moisturizers may relieve dryness; vaginal estrogen is generally avoided unless absolutely necessary and is a discussion to have with the oncology team. Store tablets at room temperature away from moisture. Acetaminophen and short courses of NSAIDs can help arthralgia, but persistent disabling joint pain warrants a switch to another agent rather than chronic analgesia. Glucosamine and chondroitin have limited evidence; supervised physical therapy and structured exercise programs have stronger support for managing aromatase-inhibitor arthralgia.

Monitoring and Follow-Up

A baseline DEXA scan to measure bone mineral density is obtained before starting letrozole, then repeated every one to two years. T-scores below -2.0 in the setting of additional fracture risk factors typically prompt addition of a bisphosphonate such as zoledronic acid, alendronate, risedronate, or denosumab. Adequate calcium and vitamin D intake is reviewed at every visit; for general background, see our article on understanding blood work and lab panels.

A fasting lipid panel is checked at baseline and annually because letrozole tends to elevate total and LDL cholesterol. Liver function tests are obtained at baseline and as clinically indicated; hepatotoxicity is uncommon but reported. Tumor markers (CA 15-3, CA 27-29) and surveillance imaging are guided by stage and recurrence risk - routine surveillance scans are not recommended for asymptomatic early-stage patients. Symptom assessment at each visit covers hot flashes, vaginal dryness, joint stiffness, mood, and sleep. Sudden or severe bone pain, vision changes, calf swelling, or new neurologic symptoms prompt urgent evaluation. After five years of adjuvant therapy, the decision to extend to seven or ten years balances individual recurrence risk, bone health, and quality of life. Cardiovascular risk should be reassessed annually, with attention to blood pressure, lipid profile, and HbA1c, because the loss of estrogen accelerates progression of subclinical atherosclerosis in some women. Annual mammography of the contralateral breast and any preserved ipsilateral breast tissue continues throughout therapy.

Special Populations

Letrozole is contraindicated in premenopausal women, pregnancy, and lactation because of teratogenicity and disruption of fetal sex steroid signaling. Pregnancy must be excluded before initiation in any patient with potential reproductive capacity. In elderly patients - the majority of those treated - no dose adjustment is needed, but baseline frailty, fall risk, and bone density carry greater weight. Renal impairment with creatinine clearance above 10 mL/min requires no dose change. Mild to moderate hepatic impairment requires no change; severe hepatic impairment with cirrhosis warrants a dose reduction to 2.5 mg every other day. Pediatric use is not established.

Drug interactions are limited - letrozole is not a strong inhibitor or inducer of major CYP enzymes - but tamoxifen given concurrently substantially lowers letrozole exposure and the two are not co-administered. Estrogen-containing medications, including topical and vaginal preparations, antagonize the drug's pharmacologic effect and should be avoided unless the oncology team specifically permits low-dose vaginal estrogen for severe genitourinary symptoms. Patients on warfarin may notice modest INR changes when starting or stopping letrozole. Bisphosphonates and denosumab are commonly co-prescribed and have no interaction. Patients with significant frailty or expected survival under one to two years may not derive net benefit from extended adjuvant therapy and deserve individualized discussion.

When to Contact Your Doctor

Call the office for sudden bone pain or fracture after minor trauma, persistent or severe joint stiffness limiting daily function, calf or thigh swelling, chest pain or sudden shortness of breath suggesting a thromboembolic event, vision changes, persistent headache, or new neurologic deficits. Yellowing of the skin or eyes, dark urine, or right upper quadrant pain warrants a same-day liver function check. Severe vaginal dryness or sexual dysfunction that affects quality of life is worth raising at any visit. New or worsening depression, anxiety, or sleep disturbance also deserves attention. Allergic symptoms including rash, swelling, or breathing difficulty require emergency care.

If you would like to discuss whether letrozole is appropriate for your treatment plan or to coordinate care with your oncologist, contact us or schedule a visit.